Combination efficacy of a GLP-1R agonist, FXR agonist & ACC inhibitor in preclinical models of NASH & Fibrosis

Time: 3:30 pm
day: Day Two


• Exploring combination approach for NASH therapy
• Analyzing preclinical models of NASH in the context of single, dual and triple treatment approaches
• Addressing underlying metabolic disease as a therapy for NASH